Nutriband Inc. (NTRB)
NasdaqCM
Price as at 30 Sept 2026, 21:55 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Nutriband Inc. trades at $7.52. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its NTRB data?
Fundamentals for NTRB come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:55 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for NTRB, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.